Muchtar, E
Dispenzieri, A
Kumar, S K
Ketterling, R P
Dingli, D
Lacy, M Q
Buadi, F K
Hayman, S R
Kapoor, P
Leung, N http://orcid.org/0000-0002-5651-1411
Chakraborty, R
Gonsalves, W
Warsame, R
Kourelis, T V
Russell, S
Lust, J A
Lin, Y
Go, R S
Zeldenrust, S
Kyle, R A
Rajkumar, S V
Gertz, M A
Article History
Received: 4 October 2016
Revised: 15 November 2016
Accepted: 22 November 2016
First Online: 1 December 2016
Competing interests
: AD received research funding from Celgene, Millennium, Pfizer and Janssen, and travel grant from Pfizer; SKK received consultancy and research funding from Celgene, consultancy and research funding from Millennium, research funding from Novartis, consultancy and research funding from Onyx, research funding from AbbVie, consultancy and research funding from Janssen, consultancy and research funding from BMS; DD received research funding from Karyopharm Therapeutics, Amgen and Millenium Pharmaceuticals; MQL received research funding from Celgene; PK received research funding from Takeda, Celgene and Amgen; MAG received honoraria from Gertz, Celgene, Onyx, Novartis, Smith Kline, Prothena, Ionis, Amgen and also received consultancy and honoraria from Millennium. The remaining authors declare no conflict of interest.